Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00250679
Other study ID # 091-061
Secondary ID
Status Completed
Phase Phase 3
First received November 4, 2005
Last updated May 29, 2012
Start date October 2005
Est. completion date October 2007

Study information

Verified date May 2012
Source Sunovion
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).


Description:

This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel group, outpatient, safety study to evaluate the long term safety of arformoterol in the treatment of subjects with COPD. Study participation will be over approximately 6 months. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.


Recruitment information / eligibility

Status Completed
Enrollment 443
Est. completion date October 2007
Est. primary completion date October 2007
Accepts healthy volunteers No
Gender Both
Age group 35 Years and older
Eligibility Key Inclusion Criteria:

- Male and female subjects must be at least 35 years old at the time of consent

- Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD

- Subjects must have a >=15 pack-year smoking history and a baseline breathlessness severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visits 1 and 2

- Female subjects <=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control

- Subjects must be in general good health.

Key Exclusion criteria:

- Subjects with a history of asthma, with the exception of asthma diagnosed in childhood

- Subjects with a blood eosinophil count >5% of total white blood cell count

- Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1

- Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Arformoterol tartrate inhalation solution
Arformoterol 15 ug BID by nebulization
Arformoterol 25 ug BID
Arformoterol 25 ug BID by nebulization
Formoterol 12 ug BID
Formoterol fumarate 12 ug BID via aerolizer/DPI
Placebo
Placebo nebule or placebo aerolizer

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations Percent of participants with the adverse event specified.
SOC = system organ class.
Six months Yes
Secondary Number of Participants With New 24-Hour Holter Monitoring Alerts New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline. Visit 6 (week 27) No
Secondary Number of Participants With Potentially Clinically Significant Glucose Evaluations Patients with glucose values that met low (<=40 mg/dL) or high (>=175 mg/dL) criteria were considered potentially clinically significant. visit 6 (week 27) No
Secondary Number of Participants With Potentially Clinically Significant Potassium Evaluations Patients with potassium values that met low (<=3 mEq/L) or high (>=6 mEq/L) criteria were considered potentially clinically significant. visit 6 (week 27) No
Secondary Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline. visit 6 (week 27) No
Secondary Inspiratory Capacity Changes From Baseline Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis. weeks 0,3,13,26 No
Secondary 6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1) The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit. weeks 0,3,13,26 No
Secondary Number of Participants With Potentially Clinically Significant Heart Rate Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm) visit 6 (week 27) No
Secondary Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler. Screening (day-14 to 0) and Treatment (week 0 - 26) No
Secondary Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication. Screening (day-14 to 0) and Treatment (week 0 - 26) No
Secondary Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week Rescue medication usage during the study. MDI stands for metered dose inhaler. Screening (day-14 to 0) and Treatment (week 0 - 26) No
Secondary Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication. Screening (day-14 to 0) and Treatment (week 0 - 26) No
Secondary Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method. weeks 0,3,13,26 No
Secondary Transitional (Relative Change in) Dyspnea Index The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests. weeks 13, 26 No
Secondary Number of Participants With an Improved Transitional Dyspnea Index The number of participants with a transitional focal score (range -9 to 9) of >=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement. weeks 13, 26 No
Secondary Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough) The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value. weeks 0,3,13,26 No
Secondary Subject Global Evaluations Change From Baseline The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study. weeks 13, 26 No
Secondary Investigator Global Evaluations Change From Baseline The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study. weeks 13, 26 No
Secondary BODE Index The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit. Baseline (visit 2), weeks 13, 26 No
Secondary 6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes Mean change from baseline in distance walked (meters) Post-Dose weeks 0, 13, 26 No
Secondary Mean Change From Baseline in St. George's Respiratory Questionnaire Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status. weeks 13, 26 No
Secondary Number of Participants With a >=4 Unit Improvement on the St. George's Respiratory Questionnaire Scores are expressed as the number of participants with >= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status. Visit 4 (week 13) , Visit 5 (week 26) No
Secondary Modified Medical Research Council Dyspnea Questionaire Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score. Baseline (visit 2), weeks 13, 26 No
Secondary Percent (%) of Participants With an Improved Transitional Dyspnea Index The percentage of participants with a transitional focal score (range -9 to 9) of >=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement. visits 4 (week 13), visit 5 (week 26) No
Secondary Percent (%) of Participants With a >=4 Unit Improvement in the St. George's Respiratory Questionaire Percent of participants with a >=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status. visit 4 (week 13), visit 5 (week 26) No
Secondary Mean Values for the 6-Minute Walk Test: Distance Walked in Meters This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes. Baseline (Visit 2), week 13, week 26 No
Secondary Mean Values for Investigator Global Evaluations The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Baseline (Visit 2), Weeks 13, 26 No
Secondary Mean Values for St. George's Respiratory Questionnaire A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status. Baseline (Visit 2), weeks 13, 26 No
Secondary Mean Values for Subject Global Evaluations The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Baseline (Visit 2), weeks 13, 26 No
Secondary Mean Values for Inspiratory Capacity Inspiratory capacity is the maximum volume that can be inhaled. Baseline (Visit 2), Weeks 3, 13, 26 No
Secondary Mean Values for Forced Expiratory Volume in One Second (FEV1) Forced Expiratory Volume in one second Baseline (Visit 2), weeks 3, 13, 26 No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy